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Genetic Variants of the DDR1 Gene Are Associated
with Vitiligo in Two Independent Brazilian
Population Samples
Caio Cesar Silva de Castro1,3, Liliane Machado do Nascimento3, Gaby Walker2, Renata Iani Werneck3,
Everson Nogoceke2 and Marcelo Ta´vora Mira3
Vitiligo is a chronic disease characterized by macules devoid of melanin and identifiable melanocytes. Adhesion
of melanocytes to the basement membrane by integrin CCN3 is mediated through collagen IV receptor DDR1.
We hypothesize that genetic variants of the DDR1 gene are associated with the occurrence of vitiligo. To test this
hypothesis, we genotyped 10 DDR1 tag single-nucleotide polymorphisms (SNPs) in 212 trios composed of an
affected child and both parents. Associated markers were then genotyped in 134 independent, unrelated individuals
with vitiligo and 134 unrelated controls. Allele Tof tag SNP rs4618569 was associated with an increased risk for vitiligo
in the family trios (P¼ 0.002, odds ratio (OR)¼ 5.27; 95% confidence interval (CI)¼ 1.59–17.40), whereas allele C of tag
SNP rs2267641 was associated with an increased risk for vitiligo in both family-based and case–control populations
(P¼ 0.01, OR¼ 3.47; 95% CI¼ 1.22–9.17; P¼ 0.04, OR¼ 6.00; 95% CI¼ 1.73–52.33, respectively). The best evidence for
association in the trios was obtained for a haplotype composed of risk alleles of markers rs4618569 and rs2267641
(P¼ 0.0006). There was an age-dependent enrichment of rs4618569 T allele and rs2267641 C allele in early-onset
affected individuals. In conclusion, we propose DDR1 as a susceptibility gene for vitiligo, possibly implicating
a defective cell adhesion in vitiligo pathogenesis.
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INTRODUCTION
Vitiligo is an acquired systemic, chronic disease with
unpredictable clinical evolution, classically characterized
by macules devoid of melanin pigment and identifiable
melanocytes (Le Poole et al., 1993). More recently, it was
shown that melanocytes are not completely absent on the
depigmented epidermis (Tobin et al., 2000). Vitiligo can be
classified into segmental or non-segmental, with different
ethiopathological origins being proposed for these two
clinical forms of disease (Hann and Lee, 1996). Non-
segmental vitiligo includes the focal and generalized
subgroups, the latter being further subdivided into vulgar,
acrofacial, and universal (Huggins et al., 2005).
The observation that healthy skin from individuals
affected by non-segmental vitiligo showed melanocyte
detachment after experimentally controlled skin friction
(Gauthier et al., 2003a) led to a theory in which vitiligo
is a primary melanocytorrhagic disorder with altered mela-
nocyte responses to skin trauma, inducing melanocyte
detachment and subsequent transepidermal loss. The authors
speculate that an autoimmune phenomenon might have
been triggered during melanocyte injury, caused by antigen
release and recognition by dendritic cells or memory T cells,
aggravating melanocyte detachment and loss (Gauthier et al.,
2003b).
Discoidin domain receptor 1 (DDR1) is a transmembrane
tyrosine kinase receptor activated by several collagens
(Vogel, 1999) that functions independently of b1 integrins
(Shrivastava et al., 1997). Collagen activation of DDR1 has
impact over several functions of human leukocytes, such as
cell differentiation, adhesion, and cytokine production
(Yoshimura et al., 2005). It is noted that DDR1 mediates
E-cadherin (Wang et al., 2009) and matricellular integrin
CCN3-dependent cell adhesion to collagen type IV (Fukuna-
ga-Kalabis et al., 2006). Functional assays show inhibition of
DDR1 by imatinib mesylate (Gleevec) (Day et al., 2008), a
potent inhibitor of BCR–ABL tyrosine kinase and c-Kit
tyrosine kinase (Buchdunger et al., 2000). Interestingly, the
use of imatinib can lead to vitiligo-like lesions (Tsao et al.,
2003; Legros et al., 2005; Brazzelli et al., 2006), possibly due
& 2010 The Society for Investigative Dermatology www.jidonline.org 1813
ORIGINAL ARTICLE
Received 1 December 2009; revised 8 January 2010; accepted 12 January
2010; published online 25 February 2010
1Department of Dermatology, Santa Casa de Miserico´rdia Hospital, Pontifical
Catholic University of Parana´, Curitiba, Parana´, Brazil; 2F. Hoffmann-La
Roche Ltd, Basel, Switzerland and 3Group for Advanced Molecular
Investigation, Graduate Program in Health Sciences, Pontifical Catholic
University of Parana´, Curitiba, Parana´, Brazil
Correspondence: Marcelo Ta´vora Mira, Group for Advanced Molecular
Investigation, Graduate Program in Health Sciences, Pontifical Catholic
University of Parana´, Rua Imaculada Conceic¸a˜o, 1155, CEP 80 215-901,
Curitiba, Parana´, Brazil. E-mail: m.mira@pucpr.br
Abbreviations: DDR1, discoidin domain receptor 1; KP, Ko¨ebner
phenomenon; LD, linkage disequilibrium; SNP, single-nucleotide
polymorphism
to inhibition of tyrosinase activity through the c-kit pathway
blockade (Cario-Andre et al., 2006). The DDR1 gene is
located between HLA-E and HLA-C genes at chromosomal
region 6p21 previously linked to vitiligo susceptibility in a
Chinese population (Liang et al., 2007).
Molecular genetic epidemiology tools have been used in
linkage and association studies aiming to locate and identify
the genes and the variants involved with vitiligo phenotypes.
Here, we present data of a combined family-based and
case–control association analysis between vitiligo and genetic
variants of the gene DDR1 involved in the regulation of
melanocyte attachment to the base membrane of the
epidermis. We selected 10 tag single-nucleotide polymorph-
isms (SNPs) that completely captured the information of
the DDR1 locus. These markers were genotyped in 596
individuals distributed in 212 family trios composed of
one affected individual and both parents, ideal for genetic
association analysis. Positive signals of association were then
tested in an independent case–control population sample of
134 vitiligo-affected individuals and 134 unrelated controls,
both groups recruited from the same geographic area in the
south of Brazil as the family trios.
RESULTS
Our recruitment strategy led to the enrollment of 596 (225
affected) individuals distributed in 188 nuclear pedigrees
from which 212 family trios could be derived. In addition to
the family trios, we also enrolled a case–control population
sample composed of 134 vitiligo patients and 134 control
individuals fully matched by age, gender, and ethnicity.
Table 1 summarizes and compares the characteristics of the
affected individuals of the two studied populations. The
median age of onset of the probands from the family-based
sample was 18.7±12.1 years, in contrast with 26.35±17.01
in the case group of the case–control sample (P¼0.0001). A
higher proportion of family history of vitiligo was observed in
the family-based group, compared with the population-based
sample (P¼ 0.001). Borderline difference in the distribution
of the clinical form of disease, classified as segmental and
non-segmental, was observed across the two samples
(P¼0.04). There were no significant differences between
the two population samples for distribution of gender and
presence of autoimmune comorbidity. The most frequent
autoimmune comorbidities observed in the family trios were
autoimmune thyroid disease (15.3%), halo nevi (7.9%), and
psoriasis (1.6%); among the cases of the case–control sample,
the proportions were 15.6, 3, and 4.5%, respectively. Of the
212 probands of the family-based sample, 81.69% self-
reported European ancestry and 15.96% reported a mixed
Caucasian, African, and Native American background.
African or Japanese ancestry was self-reported by two
individuals each, and one individual reported an Iranian
ethnic background. Affected individuals from the case–-
control population sample self-reported European (79.10%),
mixed (19.40%), and African (1.50%) ancestry. The genotyp-
ing success rate was 95% or higher for all markers tested.
Allele frequencies for all markers were in Hardy–Weinberg
equilibrium in both population samples included in the study.
Family-based association analysis
Family-based association analysis performed for all 10
SNPs detected significant association between vitiligo
and six markers of the DDR1 locus that included the
close neighboring gene GTF2H4 (rs4618569, P¼0.002;
rs1049622, P¼ 0.01; rs1049623, P¼ 0.05; rs226741,
P¼0.01; rs1049628, P¼ 0.01 and rs2074510, P¼0.04).
Out of these six associated SNPs, four were in strong linkage
disequilibrium (LD) in our population sample and two
(rs1049623 and rs2267641) were singletons. Odds ratio, as
estimated by conditional logistic regression analysis, reached
5.27 for the marker rs4618569 (IC¼ 1.59–17.40) (Table 2).
Haplotypic analysis involving the three independent tag
SNPs associated with vitiligo in the family trios revealed
strong evidence for association between vitiligo and haplo-
types composed of risk alleles of markers rs4618569
and rs2267641 (P¼0.0006), rs1049623 and rs2267641
(P¼0.008), and all three tag SNPs (P¼ 0.004) (Table 3).
To further advance the understanding of the association
effect observed, we performed a stratified analysis according
to the non-genetic covariate age of diagnosis, presence of
autoimmune comorbidity, and presence of family history of
disease. Association signals for markers rs4618569 and
rs2267641 were clearly concentrated among the trios with
early age of onset of the affected child (Table 4), using both a
cutoff of 18 and 25 years of age. For the other two covariates,
Table 1. Demographic and clinical characteristics of





Age of vitiligo onset (years)
Mean (±SD) 18.7±12.1 26.35±17.01 0.00011
Gender, n (%)2
Male 97 (43.1) 55 (41) 0.7013
Female 128 (56.9) 79 (59)
Autoimmune-comorbidity, n (%)2
With 105 (46.7) 54 (40.3) 0.293
Without 106 (47.1) 69 (51.5)
Type, n (%)2
Segmental 35 (15.5) 13 (9.7) 0.043
Non-segmental 177 (78.7) 121 (90.3)
Family history of vitiligo, n (%)2
With 92 (40.9) 37 (27.6) 0.0013
Without 115 (51.1) 89 (66.4)
1t-test.
2n = number of individuals with available information.
3w2 statistic.
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evidence for association did not resist stratification into each
subgroup.
Case–control association analysis
To validate the association results described above, DDR1
markers rs4618569, rs2267641, and rs1049623 associated
with vitiligo in the family trios were genotyped and tested for
association in an independent case–control population
sample recruited from the same geographic area as the
family trios. Linkage disequilibrium analyses confirmed
independence of all three SNPs in the case–control sample,
as observed for the family trios. Univariate analyses indicated
statistically significant association between marker
rs2267641 and vitiligo, with the same risk allele being
observed for both populations (P¼0.04, OR¼ 6.00; 95%
CI¼1.73–52.33) (Table 2; see Supplementary Table S1 online).
As the controls were matched with the cases by gender,
ethnicity, and age, no multivariate analysis was performed.
DISCUSSION
Genetic risk factors for complex traits have been intensively
investigated over the past decade and candidate genes have
been proposed for several common diseases, including
vitiligo. Here, we present strong evidence for age-dependent
association between vitiligo and variants of the DDR1 gene in
a large population sample of family trios from the south of
Table 2. Association between vitiligo and SNP markers of the DDR1 locus in two independent population samples
DDR1 DDR1 DDR1 DDR1 DDR1 GTF2H4
Marker name rs4618569 rs1049622 rs1049623 rs2267641 rs1049628 rs2074510
Family-based analysis
Bin structure1
AF 0.77 0.77 0.62 0.77 0.77 0.78
Risk allele T C T C G G
FBAT (P-value) 0.002 0.01 0.05 0.01 0.01 0.04
OR (95% CI) 5.27 (1.59–17.40) 3.36 (1.15–9.75) 1.73 (0.97–3.08) 3.47 (1.22–9.17) 3.40 (1.17–9.80) 2.91 (0.99–8.48)
Case–control
Risk allele –– –– –– C –– ––
Univariate
OR (95% CI) NS –– NS 6.00 (1.73–52.33)2 –– ––
P-value 0.04
Abbreviations: AF, allele frequency; CI, confidence interval; NS, not significant; P, reported for the best fit model; SNP, single-nucleotide polymorphism.
1A bin is composed of markers in strong linkage disequilibrium (r240.8); any SNP in the bin is sufficient to explain the observed association with vitiligo.
2Case–control sample of 134 cases (genotype frequency CC/CT-99.2%) and 134 controls (genotype frequency CC/CT-95.1%).
Table 3. Family-based association analysis between vitiligo and two- and three-marker haplotypes
Haplotype
rs4618569 rs1049623 rs2267641 Haplotype frequency Number of informative families Z P (FBAT)
T — C 0.72 35.9 3.4 0.0006
C — T 0.18 71.8 – 0.3 0.74
T — T 0.05 20.2 4.5 0.54
T T — 0.61 59.6 2.2 0.02
C T — 0.22 74.3 – 0.3 0.69
T C — 0.16 76.1 0.3 0.71
— T C 0.58 71.6 2.6 0.008
— C T 0.20 76.2 0.8 0.40
— C C 0.18 87.1 – 1.5 0.13
T T C 0.58 63.7 2.8 0.004
C C T 0.18 66.5 15.8 0.47
T C C 0.14 67.9 – 0.3 0.74
Only haplotypes with allelic frequency X0.05 were included and analyzed.
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Brazil. Family-based association and LD analysis of the
DDR1 locus revealed three independent association signals
corresponding to three tag SNPs, all intragenic to DDR1.
When two- and three-marker haplotypes were constructed
using the associated tag SNPs, association became more
evident.
Interestingly, the association signal observed for two of the
three independent disease markers was strongly dependent of
age, using as a cutoff both the average age of diagnosis in our
trios (18 years old) and the average age of diagnosis reported
in the literature (Alkhateeb et al., 2003) (25 years old,
compatible with the average age of diagnosis in our case–-
control population sample). A similar age-dependent effect
was recently observed for the LTA gene associated with
leprosy in population samples of distinct ethnic backgrounds
(Alcais et al., 2007) and is in agreement with the hypothesis
of a higher impact of genetic variants over populations with
early onset complex diseases. It is noted that a recent, large
association study on a Chinese population also revealed an
influence of age over association between vitiligo and the
promoter variant rs226977 of the gene XBP1, with borderline
significance (Ren et al., 2009).
No impact of the co-occurrence of autoimmune disorders
was observed over DDR1 association with vitiligo in our
sample. Again, the same was observed in the XBP1 study
(Ren et al., 2009), suggesting the existence of at least two
groups of vitiligo susceptibility genes, as previously indicated
by genome-wide linkage results (Spritz et al., 2004): those
acting over an autoimmune background, such as NALP1 (Jin
et al., 2007), and others controlling additional, independent
physiopathological mechanisms, such as DDR1 and XBP1.
Finally, both DDR1 and XBP1 (Ren et al., 2009) associations
are independent of the presence of family history of disease.
Genetic association studies involving a large number of
tests are always prone to spurious positive findings because of
multiple testing. To confirm association, all three DDR1 tag
SNPs associated with vitiligo in the family-based population
were tested on an independent case–control sample, with
positive evidence for association again being obtained for
marker rs2267641 (P¼ 0.04). It is possible that lack of
association between the other two tag SNPs and vitiligo in the
case–control sample is due to the age effect observed in the
family trios—mean age of diagnosis of the cases of the
case–control population was higher than 25 years, perhaps
indicating a weaker genetic component controlling suscep-
tibility to the disease as compared with the family-based
sample. Nevertheless, perfect replication of the association
signal for marker rs2267241, with the same risk allele on
both population samples, argues strongly in favor of DDR1
as a vitiligo susceptibility gene.
There are limitations in our study that should be
addressed: (i) the loss of the association signal when the
population sample of trios was stratified by the co-occurrence
of autoimmune diseases and family history of vitiligo may be
simply a consequence of loss of power due to a decrease in
the sample size; (ii) the non-segmental clinical form of vitiligo
is over-represented in both our samples—therefore, it is
possible that DDR1 is a gene associated exclusively with this
particular form of disease. In fact, when segmental cases are
removed from the family-based analysis, association persists
for two out of three tag SNPs (rs4618569, P¼ 0.03 and
rs2267641, P¼0.02) even with the reduction in the number
of informative families; (iii) the small sample size of the
case–control population certainly limits the power of the
replication experiment. These first three limitations can be
addressed by expanding the population samples. Finally, the
MHC/HLA locus is classically known as presenting a very
complex LD structure (Stenzel et al., 2004) and it is possible
that the DDR1 alleles associated with vitiligo are in LD with
the true causative variant located elsewhere within the
region. Several HLA alleles have been associated with
susceptibility to vitiligo in different populations (Zhang
et al., 2004; Yang et al., 2005; Abanmi et al., 2006). Further
studies should address whether the association detected for
DDR1 markers is independent from other gene variants
associated with vitiligo already described for this locus.
There is no obvious functional impact of the DDR1 tag
SNPs associated with vitiligo in this study. In addition, none
of the known non-synonymous DDR1 SNPs belong to any of
the three associated bins described here. However, SNPs
rs2267641 and rs1049623 are exonic, synonymous variants.
Mechanisms by which synonymous SNPs could affect the
protein function include impact over mRNA secondary
structure with consequences on the level of protein expres-
sion (Nackley et al., 2006). Furthermore, it has been recently
shown that silent polymorphisms may deeply alter protein
function – the authors propose a mechanism of modification
of timing of co-translational folding and protein localization
in specific cell compartments (Kimchi-Sarfaty et al., 2007).
How the associated variants of DDR1 affect gene and,
consequently, cell function remains to be investigated. One
powerful strategy would be systematic comparative sequen-
cing of the entire coding region of DDR1 that will eventually
lead to the identification of the true vitiligo causative variants.
Further functional experiments involving tools such as gene
expression and RNA stability analysis, gene silencing, and









rs4618569 T p18 0.007 1.88 (1.18–3.01)
418 0.63 1.38 (0.36–5.30)
p25 0.009 6.87 (1.6–29.18)
425 0.50 2.12 (0.23–18.83)
rs2267641 C p18 0.03 1.64 (1.02–2.62)
418 0.10 1.85 (0.88–3.89)
p25 0.03 3.76 (1.1–12.62)
425 0.35 2.66 (0.33–21.31)
Number of trios: 110 For ages p18 and 89 for 418 years old; 143 for
ages p25 and 56 for 425 years old; 13 individuals, data not available.
1P reported for the best fit model.
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immunohistochemistry would then be mandatory to establish
the molecular defect responsible for the occurrence of the
disease.
There is no consensus regarding exactly how melanocytes
succumb to vitiligo (Schallreuter et al., 2008). Here, we
present DDR1 as a susceptibility gene for vitiligo, high-
lighting a possible defective adhesion role in vitiligo
pathogenesis: on the basis of our findings, one can speculate
that vitiligo patients harboring DDR1 variants have altered
melanocyte adhesion to the basement membrane, particu-




This study was performed between December 2004 and November
2008. Affected individuals, their parents, and independent controls
were enrolled from the Brazilian southern states of Parana´ and Santa
Catarina. Control individuals, matched with the cases by age,
gender, and ethnicity were recruited from primary care centers
located in the same geographical areas of the cases. Eligibility
criteria for the control group were no self-reported history of
autoimmune and inflammatory disease and no sign of vitiligo on
complete physical examination by an experienced dermatologist. All
patients and their relatives were ascertained at the outpatient vitiligo
clinic of the Santa Casa de Miserico´rdia Hospital and a private
medical office. On agreement to participate, the patient was asked to
reach their parents and siblings to inform about the study and suggest
voluntary contact with the investigators for possible enrollment and
data collection.
All patients and relatives had their vitiligo status defined or
confirmed by one single dermatologist (CCSC), who also performed
disease classification of the confirmed cases. Diagnosis was
performed on the basis of clinical findings after complete physical
examination and Wood’s lamp screening, and most of the
individuals included were followed up during the period of the
study. When necessary, confirmation of affected status was obtained
on biopsy and histopathological examination.
Confirmed cases of vitiligo were classified as segmental and non-
segmental disease, the latter including the focal, acrofacial, vulgar,
and universal clinical forms. Patients were characterized as affected
by segmental vitiligo if presenting unilateral or bilateral macules in
a dermatomal or quasi-dermatomal distribution in one or more
dermatomes. Focal vitiligo was characterized by one or more
macules confined in a single specific area of the skin in a non-
dermatomal distribution. Acrofacial vitiligo was characterized by
macules in distal digits, and as periorificial on face and ano-genital
areas. Minimal duration of acrofacial and focal vitiligo disease
considering ‘‘stable vitiligo’’ was 1 year (Taieb and Picardo, 2007).
Patients presenting lesions beyond acrofacial areas, such as the
thorax, abdomen, thighs, legs, buttocks, arms, neck, and axillae,
were classified as affected by vulgar vitiligo. Individuals affected by
universal vitiligo presented few remaining normal macules of
pigmentation on extended skin exam.
After diagnosis, all individuals with confirmed cases answered a
questionnaire to determine gender, age of onset (self-reported as the
date when the first white spot was observed), presence of family
history of vitiligo as reported by the affected individual or a close
relative, and occurrence of autoimmune diseases in the nuclear
family, for example, among parents or siblings of the vitiligo-affected
individual. Control individuals were asked about gender, age, and
inflammatory and autoimmune diseases. All enrolled individuals had
a blood sample collected and used for genomic DNA extraction
following classic salting-out protocol (John et al., 1991).
The study was approved by the Pontifical Catholic University of
Parana´ Ethics Committee and was conducted according to the
principles of the Declaration of Helsinki. Written, informed patient
consent was obtained for all individuals enrolled.
Marker selection and genotyping
Tag SNP markers capturing the entire information of the DDR1 locus
were selected according to the information available at the
International HapMap Project website, release 21. All selected
markers presented a minor allele frequency of 0.2 or more in at least
four populations: Caucasian, Japanese, Yoruba, and Chinese Han.
The cutoff parameter to define LD between two markers
was an r240.8. Following these criteria, the following tag SNPs
were included: rs4618569, rs1264323, rs1264320, rs2267641,
rs1049622, rs1049623, rs1049628, rs1264319, rs2074510, and
rs1264307, the last two markers spanning into the neighboring gene
GTF2H4. SNPs were genotyped in one or both of the following
platforms: (i) Applied Biosystems StepOnePlus or Applied Biosys-
tems 7500 polarized fluorescence TaqMan assay (Lee et al., 1993);
(ii) SEQUENOM MassARRAY, which uses the iPLEX assay to
incorporate mass-modified terminal nucleotides in the SBE step that
are then detected by matrix-assisted laser desorption/ionization time
of flight (MALDI-TOF) mass spectrometry (Griffin and Smith, 2000).
Genotypes were automatically called using the appropriate software
with subsequent manual checking of accuracy. Five SNPs
(rs4618569, rs12644323, rs1049622, rs1264320, and rs2267641)
were genotyped in duplicate in the family-based sample.
Statistical methods
Demographic and clinical variables of the cases from both the
family-based and the case–control population samples were com-
pared using w2 and the t-test, when indicated.
On genotyping, families presenting Mendelian inconsistencies
were removed from the analysis. Hardy–Weinberg equilibrium and
LD estimations were carried out using Haploview software (Barrett
et al., 2005). SNP bins were constructed using pairwise r2 estimates
obtained from parental data from the family trios and the control
group of the case–control sample, and were defined as a not
necessarily contiguous set of variants, in which at least one SNP has
r240.8 with all the other SNPs of the bin (Hinds et al., 2005).
As the family-based sample consisted of trios with no missing
parental information, a classic transmission disequilibrium test was
performed for family-based association analysis, as implemented by
FBAT software V. 2.0.2.c (Horvath et al., 2001). FBAT was also used
for family-based haplotypic association analysis, and P-values were
adjusted using the Monte Carlo haplotype test using the hbat
procedure. For estimation of OR, alleles for which positive evidence
for association was detected were analyzed by conditional logistic
regression analysis (Schaid and Rowland, 1998) using the PHREG
procedure, as implemented in SAS software v.9.1. The population-
based study was carried out using classical univariate techniques as
implemented in SAS software v.9.1.
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